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Left ventricular assist devices (LVADs) provide great benefit to patients 
with advanced systolic heart failure, including those awaiting heart 
transplantation. As there is a limited supply of donor hearts, increasing 
numbers of patients are supported by LVAD therapy for prolonged 
periods of time. As with most advances, LVADs carry with them both 
benefits and challenges.  
 
In this issue of Trends in Cardiovascular Medicine, Kadado et al. review 
the problem of cardiac arrhythmia following LVAD implantation.1 Their 
article will be a valuable resource for anyone who cares for these 
patients, as both atrial and ventricular arrhythmias are common among 
the heart failure (HF) population. The authors summarize for us the 
epidemiology, prevention, and management of these arrhythmias.  
 
 
Atrial Arrhythmias 
As Kadado et al. explain, HF often coexists with atrial fibrillation (AF), 
and the synergistic detrimental impact of the combined conditions is 
more than additive.2,3 While AF’s hemodynamic effects are largely 
mitigated by the LVAD’s support of the left heart’s output, still AF may 
impact negatively on right heart function. In addition, AF carries with it 
a significant risk of thrombosis and thromboembolism (TE). The 
presence of an LVAD may raise an AF patient’s thromboembolic risk, 
while also paradoxically exacerbating the bleeding risk associated with 
anticoagulation (AC) for TE prophylaxis. 
 
The treatment of atrial arrhythmias in LVAD patients shares some 
similarities with treatment in those without LVADs, but some 
differences exist as well. Control of the ventricular rate is a cornerstone 
of therapy for AF in the LVAD patient, as rhythm control often produces 
no change in the assisted heart’s output. LVAD patients already require 
AC, but AC therapy often must be intensified in the presence of AF. 
Kadado et al. include an important section regarding the elevated 
bleeding risk associated with LVAD patients’ acquired von Willebrand 
Syndrome and their propensity toward arteriovenous malformations. 
The resultant increased bleeding risk is important for many aspects of 
care, including decision making regarding implantation of pacemakers 
or implantable cardioverter-defibrillators (ICDs; see below). 
 
 
Ventricular Arrhythmias 
Because LVADs can effectively replace cardiac output with little or even 
no contribution from the native heart, oftentimes even prolonged 
periods of otherwise deadly ventricular arrhythmias (VAs) can be well 
tolerated.4 However, VAs may also have ill consequences, ranging from 
harmless palpitations to dangerous effects such as progressive right 
heart failure. In addition, embolic injury has been described, 
presumably due to thrombus formation related to tachyarrhythmic 
myocardial standstill.5  
 
VAs in the LVAD population can have similar or different mechanisms as 
those in HF patients without LVADs. Patients with or without LVADs 
may have VAs related to scar-mediated reentry, ischemia, or electrolyte 
abnormalities, which may be further exacerbated by the infusion of 
inotropes and pressor medication. Kadado et al. list for us some 
additional factors that are specific to those with LVADs: mechanical 
“suck-down” events, postoperative inflammation, and electrical reentry 
around the LV apical cannula itself. In addition, the presence of an LVAD 
may complicate attempts at management via catheter ablation (though 
ablative therapy has been described as successful, in small series also 
cited in the Kadado paper). 
 
Kadado et al. offer practical recommendations for the evaluation of VT 
in LVAD patients. These include searching for underlying reversible 
causes of VT, weaning pressors and maximizing beta blockade, as well 
as volume repletion and/or pump speed reduction in the case of suck-
down events (which often are evident via echocardiography). 
 
Another cornerstone of VA therapy is ICD implantation. The benefit of 
ICDs in the LVAD population is incompletely understood at the present 
time. While patients are unlikely to die suddenly in the presence of a 
functioning LVAD, sustained arrhythmias may cause progressive right 
heart failure or other problems that lead to more gradual 
decompensation and death. The most recent societal guidelines and 
expert consensus statements support the use of ICDs in patients 
awaiting transplant or in those with LVADs either as “destination” 
therapy or as a “bridge to transplant.”6,7 However, as Kadado et al. 
discuss in their article, several retrospective analyses of ICD therapy in 
patients with LVADs have been published, and these studies come to 
varying conclusions about ICDs’ value in this population. Clearly, a 
randomized controlled trial is needed to answer this question.  
 
Of course, there can be downsides to ICD implantation, including the 
high associated cost. The added risks of ICD implant in LVAD patients, 
including bleeding and infection, must also be considered. Another 
complication related to ICDs is the possibility of inappropriate shocks, 
which can be damaging not only to the patient’s psychological health 
but also to myocardial function. Kadado et al. support MADIT-RIT-like 
programming designed to minimize inappropriate shocks. The authors 
also offer other guidance such as programming for 
aggressive/prolonged antitachycardia pacing, thereby targeting 
painless termination of the monomorphic ventricular tachycardias that 
are characteristic of patients with LVADs.  
 
Conclusion 
In their excellent review, Kadado et al. summarize for the clinician the 
incidence, prevention, and treatment of arrhythmias in the LVAD 
population. The insight gained from reading this work will assist with 
caring for, and improving outcomes for, this deserving group of patients.  
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